News

Apexian Pharmaceuticals Opens Phase 1 Clinical Study of APX3330 in Patients with Solid Tumors

Indianapolis, IN – Apexian Pharmaceuticals, a clinical-stage biopharmaceutical company, has announced the opening of a clinical trial for patients with advanced solid tumors. The study involves APX3330, an orally administered inhibitor of APE1/Ref-1, a dual-function protein that plays a critical role in promoting and maintaining a broad variety of cancers. Details of the study, including eligibility criteria, the location of participating clinical centers and referral...

Apexian Pharmaceuticals is Closing a Series A Round to Initiate Phase 1 Trial

Indianapolis, IN – November 29, 2017 – Apexian Pharmaceuticals, an Indiana-based clinical stage biotechnology company developing novel compounds to treat cancer, announced today that they are closing their Series A round. This financing follows previous investments as well as numerous grants and awards by the company since its founding. Proceeds will be used to initiate their phase 1 clinical study for APX3330 a novel first...

Apexian Pharmaceuticals to participate in the National Cancer Institute’s SBIR Investor Initiatives program

Indianapolis-based Apexian Pharmaceuticals, a clinical-stage biotech company developing novel compounds to treat cancer by leveraging intellectual property discovered at the Indiana University School of Medicine has been selected to participate in the National Cancer Institute’s SBIR Investor Initiatives program. As part of the program, Dr. Richard Messmann — Apexian’s chief medical officer — will present at the BioNetwork Partnering Summit taking place Oct. 23-25 in...